The use of SGLT2 inhibitors has been a game-changer in the treatment of heart failure (HF). Now, another drug class has ...

The US regulator has cleared use of Kerendia (finerenone) for the treatment of heart failure patients who have a left ...

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

Bayer AG BAYRY announced that the FDA has approved a label expansion of kidney disease drug Kerendia (finerenone). The ...

Approval of Kerendia was based on results from the Phase III FINEARTS-HF trial, which demonstrated statistically significant ...

Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...

The going has been good for the German pharmaceutical giant Bayer BAYRY this year. Shares have surged 62.9% year to date ...

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic ...

WHIPPANY, N.J.–(BUSINESS WIRE)–Jul 9, 2021–Bayer announced today the United States (U.S.) Food and Drug Administration (FDA) has approved KERENDIA (R) (finerenone), a first-in-class ...

Thanks to hefty sales increases of Kerendia and Nubeqa, Bayer’s pharma division weathered the loss of exclusivity in the U.S. of Xarelto in Q1.

Bayer AG said the drug Kerendia has shown potential to significantly reduce sudden cardiac death among patients with chronic kidney disease and diabetes, a boost to its potential as a blockbuster ...